Form 8-K for CV Therapeutics Inc.

Other Events and Financial Statements & Exhibits

ITEM 5. OTHER EVENTS

On October 2, 2003, we filed a registration statement on Form S-3, which registration statement was amended pursuant to pre-effective amendment no. 1 filed on February 5, 2004, registering up to an aggregate of $300,000,000 of our securities, $47,500,000 of which was carried over from a registration statement on Form S-3 that we filed on January 4, 2001, which was amended pursuant to pre-effective amendment no. 1 filed on January 12, 2001.

On February 26, 2004, we entered into a Common Stock Purchase Agreement with Mainfield Enterprises, Inc., pursuant to which we agreed to issue and sell 1,609,186 shares of our common stock at a purchase price of $15.5358 per share, for aggregate gross proceeds of approximately $25,000,000. The shares will be issued pursuant to the registration statements referenced above. We intend to deliver the shares on or about March 2, 2004.

The foregoing description is qualified in its entirety by reference to the Common Stock Purchase Agreement, dated as of February 26, 2004, by and between Mainfield Enterprises and us, which is incorporated by reference into this report.

ITEM 7. FINANCIAL STATEMENTS,
PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits.
10.1 Common Stock Purchase Agreement, dated as of February 26, 2004, by and between the Company and Mainfield Enterprises, Inc.